Telomeres and telomerase in ageing and cancer

被引:3
|
作者
Cowell, JK [1 ]
机构
[1] Cleveland Clin Fdn, Lerner Res Inst, Ctr Mol Genet, Cleveland, OH 44195 USA
关键词
D O I
10.1007/s11357-999-0007-2
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Telomeres lie at the ends of human chromosomes and contain long tandem repeats of a simple nucleotide sequence. Because DNA replication cannot proceed to the very end of chromosomes, copies of these repeats are lost at each cell division. If the telomeres shorten below a critical length, the cells will eventually die as a result of genomic instability. Aging cells usually avoid death by entering senescence before the critical telomere length is reached. Malignantly transformed, immortal cells overcome senescence but they must still avoid the final, critical shortening of telomeres to survive. In the vast majority of cases, tumor cells achieve this by activating the telomerase enzyme, a ribonucleoprotein complex which repairs the end of chromosomes and prevents telomere shortening. Normal mortal cells do not normally express telomerase, although some stem cell populations which must regenerate thought the life span of the organism, retain enzyme activity. Cellular senescence can be overcome by inducing telomerase expression in mortal cells, firmly establishing the role of telomere length in the senescence signaling pathway. In tumor cells, the evidence of a role for telomerase in immortality is still largely correlative, with 80-90% of tumors expressing telomerase activity. To establish whether telomerase activity is important in maintaining the malignant phenotype, attempts have been made to inactivate it in tumor cells, using a variety of approaches, where there is evidence that disrupting telomerase function can result in the induction of apoptosis. The background and implications of these observations is discussed.
引用
收藏
页码:59 / 64
页数:6
相关论文
共 50 条
  • [41] Cancer and Telomeres-An ALTernative to Telomerase
    Shay, Jerry W.
    Reddel, Roger R.
    Wright, Woodring E.
    SCIENCE, 2012, 336 (6087) : 1388 - 1390
  • [42] Telomeres and telomerase as targets for cancer therapy
    Zimmermann, S.
    Martens, U. M.
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2007, 64 (7-8) : 906 - 921
  • [43] AGING AND CANCER - ARE TELOMERES AND TELOMERASE THE CONNECTION
    SHAY, JW
    MOLECULAR MEDICINE TODAY, 1995, 1 (08): : 378 - 384
  • [44] Aging and cancer: Are telomeres and telomerase the connection?
    Shay, J. W.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2008, 49 (07) : 515 - 515
  • [45] Dietary restriction ameliorates haematopoietic ageing independent of telomerase, whilst lack of telomerase and short telomeres exacerbates the ageing phenotype
    Al-Ajmi, Nouf
    Saretzki, Gabriele
    Miles, Colin
    Spyridopoulos, Ioakim
    EXPERIMENTAL GERONTOLOGY, 2014, 58 : 113 - 119
  • [46] Telomeres and telomerase
    Dahse, R
    Fiedler, W
    Ernst, G
    PATHOLOGE, 1997, 18 (06): : 425 - 429
  • [47] Telomeres and telomerase
    Pawelec, G
    Effros, RB
    JOURNAL OF ANTI-AGING MEDICINE, 2000, 3 (04): : 361 - 363
  • [48] Telomeres and telomerase as targeted therapies in cancer treatment
    Souiden, Y.
    Bouraoui, A.
    Chaieb, K.
    Mahdouani, K.
    BULLETIN DU CANCER, 2010, 97 (09) : 1087 - 1104
  • [49] Telomeres, telomerase and cancer: an up-date
    Karl Dhaene
    E. Van Marck
    Reza Parwaresch
    Virchows Archiv, 2000, 437 : 1 - 16
  • [50] Telomeres and telomerase in the clinical management of colorectal cancer
    C. Piñol-Felis
    T. Fernández-Marcelo
    J. Viñas-Salas
    C. Valls-Bautista
    Clinical and Translational Oncology, 2017, 19 : 399 - 408